This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vella-Brincat, J. Articles by Macleod, A D Search for Related Content PubMed PubMed Citation Articles by Vella-Brincat, J. Articles by Macleod, A D Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB HALOPERIDOL Social Bookmarking                         What's this?

Haloperidol in palliative care

A D (Sandy) Macleod

Nurse Maude Hospice, Christchurch

Haloperidol is one of 20 ‘essential’ medications in palliative care. Its use is widespread in palliative care patients. The pharmacology of haloperidol is complex and the extent and severity of some of its adverse effects, particularly extrapyramidal adverse effects (EPS), may be related to the route of administration. Indications for the use of haloperidol in palliative care are nausea and vomiting and delirium. Adverse effects include EPS and QT prolongation. Sedation is not a common adverse effect of haloperidol. It is important that palliative care practitioners have a comprehensive understanding of the indications, doses, adverse effects and pharmacology of haloperidol. This review is intended to address these issues.

Key Words: cytochrome P450 • extrapyramidal adverse effects • haloperidol • QT interval prolongation

Palliative Medicine, Vol. 18, No. 3, 195-201 (2004)
DOI: 10.1191/0269216304pm881oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. H. Bush and E. Bruera The Assessment and Management of Delirium in Cancer Patients Oncologist, October 1, 2009; 14(10): 1039 - 1049. [Abstract] [Full Text] [PDF]

				J. G. J. Hasselaar, S. C. A. H. H. V. M. Verhagen, A. P. Wolff, Y. Engels, B. J. P. Crul, and K. C. P. Vissers Changed Patterns in Dutch Palliative Sedation Practices After the Introduction of a National Guideline Arch Intern Med, March 9, 2009; 169(5): 430 - 437. [Abstract] [Full Text] [PDF]

				C.-C. Chu, J.-P. Shieh, J.-I. Tzeng, J.-Y. Chen, Y. Lee, S.-T. Ho, and J.-J. Wang The Prophylactic Effect of Haloperidol Plus Dexamethasone on Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopically Assisted Vaginal Hysterectomy Anesth. Analg., May 1, 2008; 106(5): 1402 - 1406. [Abstract] [Full Text] [PDF]

				C. White, A. McPherson, M.-A. McCann, A. Sadler, and J. Fyvie Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic Palliative Medicine, April 1, 2006; 20(3): 215 - 216. [Abstract] [PDF]

				J. A Spiller and J. C Keen Hypoactive delirium: assessing the extent of the problem for inpatient specialist palliative care Palliative Medicine, January 1, 2006; 20(1): 17 - 23. [Abstract] [PDF]